glucagon-like peptide 2-(2-33) (Rat) [3720]
glucagon-like peptide 2-(2-33) (Rat)
| SMILES |
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC |
| InChIKey |
OQGQYLSDVZWIPO-QSSAVJFTSA-N |
| Sequence |
ADGSFSDEMNTILDNLATRDFINWLIQTKITD |
| HELM |
PEPTIDE1{A.D.G.S.F.S.D.E.M.N.T.I.L.D.N.L.A.T.R.D.F.I.N.W.L.I.Q.T.K.I.T.D}$$$$ |
Chemical Properties
| Hydrogen bond acceptors |
52 |
| Hydrogen bond donors |
53 |
| Rotatable bonds |
122 |
| Log P |
-16.796 |
| Molecular weight (Da) |
3656.8 |
| Stereochemistry info |
partial |
Bioactivities
|
| Receptor |
Activity |
Source |
| Protein |
Gene |
Species |
Family |
Class |
Type |
Min |
Avg |
Max |
Database |
|
|
|
|
|
|
|
|
|
|
|
| Receptor |
Activity |
Source |
| Protein |
Gene |
Species |
Family |
Class |
Type |
Min |
Avg |
Max |
Database |
|
|
|
|
|
|
|
|
|
|
glucagon-like peptide 2-(2-33) (Rat)
Drug properties
| Molecular type |
Peptide |
| Physiological/Surrogate |
Endogenous |
| Approved drug |
No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0
Compound is not listed as a drug.